EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Assessment) was downgraded by StockNews.com equity researchers from a “hold” rating to a “sell” rating in a report released Tuesday.
Separately, HC Wainwright raised its price target on EyePoint Pharmaceuticals from $24.00 to $25.00 in a Thursday, August 4 research note. One analyst rated the stock with a sell rating and four gave the stock a buy rating. According to MarketBeat.com, the stock currently has a “Moderate Buy” consensus rating and an average target price of $27.00.
EyePoint Pharmaceuticals stock up 2.7%
The NASDAQ EYPT traded down $0.14 during Tuesday’s trading, hitting $5.37. 98,475 shares of the company were traded, against an average volume of 167,702. EyePoint Pharmaceuticals has a 12-month low of $4.89 and a 12-month high of $21.50. The company has a fifty-day simple moving average of $7.06 and a 200-day simple moving average of $8.69. The company has a market capitalization of $182.97 million, a P/E ratio of -2.49 and a beta of 1.10. The company has a current ratio of 6.17, a quick ratio of 6.07 and a debt ratio of 0.19.
EyePoint Pharmaceuticals Institutional Trading
Several hedge funds have recently increased or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in EyePoint Pharmaceuticals in Q1 for $30,000. Amalgamated Bank acquired a new position in shares of EyePoint Pharmaceuticals in Q1 worth approximately $31,000. Cubist Systematic Strategies LLC increased its position in EyePoint Pharmaceuticals by 46.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,600 shares of the company worth $52,000 after acquiring 2,099 additional shares in the last quarter. Royal Bank of Canada increased its stake in EyePoint Pharmaceuticals by 31.9% during the 1st quarter. Royal Bank of Canada now owns 7,934 shares of the company valued at $97,000 after buying 1,918 more shares last quarter. Finally, Principal Financial Group Inc. acquired a new stake in EyePoint Pharmaceuticals during the 2nd quarter at a value of $97,000. Institutional investors hold 88.65% of the company’s shares.
About EyePoint Pharmaceuticals
(Get an evaluation)
EyePoint Pharmaceuticals, Inc, a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China and the United Kingdom. The company offers ILUVIEN, a sustained-release injectable micro-insert for the treatment of diabetic macular edema; YUTIQ, an intravitreal fluocinolone acetonide implant for intravitreal injection for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye; and DEXYCU, an intraocular suspension of dexamethasone, for the treatment of postoperative eye inflammation, including treatment after cataract surgery.
Read more
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to contact@marketbeat.com.
Before you consider EyePoint Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and EyePoint Pharmaceuticals was not on the list.
While EyePoint Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here
